The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. held its seventh meeting of the fourth session of the Board of Directors, where various resolutions were discussed and approved, including the annual work report for 2024. The meeting, which complied with relevant Chinese regulations, signifies the company’s ongoing commitment to transparency and strategic planning, potentially impacting its market positioning and stakeholder confidence.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development, production, and commercialization of innovative drugs, particularly in the field of oncology and autoimmune diseases.
YTD Price Performance: 20.55%
Average Trading Volume: 1,550,382
Technical Sentiment Signal: Hold
Current Market Cap: HK$26.82B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.